Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias

Overview

Journal Am J Respir Crit Care Med

Specialty Critical Care

Date 2022 Aug 11

PMID 35950929

Authors

Samy Suissa

Karine Suissa

Affiliations

Soon will be listed here.

Citing Articles

Antifibrotic drug treatment of patients with idiopathic pulmonary fibrosis in Sweden: A registry-based observational study.

Carlson L, Kalafatis D, Pesonen I, Magnusson J, Skold M Chron Respir Dis. 2024; 21:14799731241299443.

PMID: 39532288 PMC: 11558727. DOI: 10.1177/14799731241299443.

The hazard of using the Poisson model to cope with immortal time bias in the case of time-varying hazard.

Rea F, Morabito G, Corrao G, Cantarutti A BMC Med Res Methodol. 2024; 24(1):272.

PMID: 39522028 PMC: 11549743. DOI: 10.1186/s12874-024-02396-y.

An Eternal Dilemma: Exposing the Impact of Immortal Time Bias on Antifibrotic Effectiveness.

Kyle A, Dempsey T Ann Am Thorac Soc. 2024; 21(10):1383-1384.

PMID: 39352177 PMC: 11451883. DOI: 10.1513/AnnalsATS.202407-717ED.

Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias.

Hozumi H, Miyashita K, Nakatani E, Inoue Y, Yasui H, Suzuki Y Respir Res. 2024; 25(1):293.

PMID: 39085869 PMC: 11293013. DOI: 10.1186/s12931-024-02922-y.

Effect of Antifibrotic Use on Mortality in Patients with Idiopathic Pulmonary Fibrosis.

Xu H, Hui S, Lee J, Zhang Z, Boente R Ann Am Thorac Soc. 2024; 21(10):1407-1415.

PMID: 39012168 PMC: 11451888. DOI: 10.1513/AnnalsATS.202312-1054OC.

References

Suissa S . Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2007; 167(4):492-9. DOI: 10.1093/aje/kwm324. View

Tran T, Assayag D, Ernst P, Suissa S . Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis: A Population-Based Cohort Study. Chest. 2020; 159(2):673-682. DOI: 10.1016/j.chest.2020.08.2080. View

Lee E, Lee T, Hong Y, Ryoo J, Heo J, Gil B . Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study. PLoS One. 2021; 16(12):e0261684. PMC: 8699661. DOI: 10.1371/journal.pone.0261684. View

Adegunsoye A, Alqalyoobi S, Linderholm A, Bowman W, Lee C, Pugashetti J . Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest. 2020; 158(4):1526-1534. PMC: 7545483. DOI: 10.1016/j.chest.2020.04.066. View

Nathan S, Brown A, Mogulkoc N, Soares F, Collins A, Cheng J . The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis. Respir Med. 2020; 170:106068. DOI: 10.1016/j.rmed.2020.106068. View

Canestaro W, Forrester S, Raghu G, Ho L, Devine B . Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis. Chest. 2016; 149(3):756-66. DOI: 10.1016/j.chest.2015.11.013. View

Raghu G, Selman M . Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med. 2015; 191(3):252-4. DOI: 10.1164/rccm.201411-2044ED. View

Jegal Y, Park J, Kim S, Yoo H, Jeong S, Song J . Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry. Tuberc Respir Dis (Seoul). 2021; 85(2):185-194. PMC: 8987666. DOI: 10.4046/trd.2021.0123. View

Kaunisto J, Salomaa E, Hodgson U, Kaarteenaho R, Kankaanranta H, Koli K . Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry. ERJ Open Res. 2019; 5(3). PMC: 6612605. DOI: 10.1183/23120541.00170-2018. View

10.

Suissa S, Moodie E, DellAniello S . Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiol Drug Saf. 2016; 26(4):459-468. DOI: 10.1002/pds.4107. View

11.

Suissa S, DellAniello S . Time-related biases in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2020; 29(9):1101-1110. DOI: 10.1002/pds.5083. View

12.

Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T . Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest. 2021; 160(5):1751-1763. DOI: 10.1016/j.chest.2021.06.049. View

13.

Jo H, Glaspole I, Grainge C, Goh N, Hopkins P, Moodley Y . Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J. 2017; 49(2). DOI: 10.1183/13993003.01592-2016. View

14.

Nathan S, Albera C, Bradford W, Costabel U, Glaspole I, Glassberg M . Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2016; 5(1):33-41. DOI: 10.1016/S2213-2600(16)30326-5. View

15.

Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M . Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J. 2020; 56(2). DOI: 10.1183/13993003.02279-2019. View

16.

Suissa S, Assayag D . Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?. Eur Respir J. 2021; 57(3). DOI: 10.1183/13993003.04562-2020. View

17.

Leuschner G, Klotsche J, Kreuter M, Prasse A, Wirtz H, Pittrow D . Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study. Front Med (Lausanne). 2020; 7:601279. PMC: 7703706. DOI: 10.3389/fmed.2020.601279. View

18.

Lancaster L, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Loaiza L . Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019; 6(1):e000397. PMC: 6530503. DOI: 10.1136/bmjresp-2018-000397. View

19.

Kang J, Han M, Song J . Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis. Sci Rep. 2020; 10(1):15620. PMC: 7515864. DOI: 10.1038/s41598-020-72607-1. View

20.

Rogliani P, Calzetta L, Cavalli F, Matera M, Cazzola M . Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Pulm Pharmacol Ther. 2016; 40:95-103. DOI: 10.1016/j.pupt.2016.07.009. View